Literature DB >> 8014879

Different signal transduction pathways are coupled to the nucleotide receptor and the P2Y receptor in C6 glioma cells.

W W Lin1, D M Chuang.   

Abstract

In C6 glioma cells, extracellular ATP and other nucleotide analogs stimulated phosphoinositide (PI) breakdown and inhibited isoproterenol-induced cyclic AMP (cAMP) accumulation. The rank orders of potencies of 15 nucleotide analogs for both responses were clearly different. ATP and adenosine 5'-O-(3-thiotriphosphate) are the most potent agonists for stimulating PI hydrolysis; 2-methylthio-ATP (2-MeSATP) is the most potent agonist for inhibiting cAMP accumulation. P1-mediated responses of PI turnover and cAMP formation are not present in C6 glioma cells. Pertussis toxin (PTX) blocked the nucleotide-induced inhibition of cAMP accumulation but exerted no effect on inositol phosphate formation. Short-term treatment with phorbol 12-myristate 13-acetate inhibited both signal transduction pathways. The effects of three P2 purinergic antagonists, suramin, reactive blue and 4,4'-diisothiocyanatostilbene sulfonic acid (DIDS), on ATP- and 2-MeSATP-induced stimulation of PI turnover and inhibition of cAMP formation, respectively, were compared. For stimulating PI turnover, suramin is a competitive antagonist (pA2, 4.4); reactive blue and DIDS are noncompetitive antagonists at 30 microM and 100 microM, respectively. For the inhibition of cAMP formation, reactive blue and DIDS competitively antagonized the response of 2-MeSATP (pA2 values, 6.3 for reactive blue and 5.7 for DIDS); suramin was only slightly effective at 100 microM. It was concluded that the nucleotide receptor is linked to phospholipase C by a PTX-insensitive Gp protein and the P2Y receptor is linked to adenylyl cyclase by a PTX-sensitive Gi protein. Suramin is a competitive antagonist for the nucleotide receptor; reactive blue and DIDS are more selective antagonists for the P2Y receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014879

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  P2Y(AC)(-)-receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase.

Authors:  P Claes; B Grobben; K Van Kolen; D Roymans; H Slegers
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

2.  SK & F 96365 inhibits carbachol-induced phosphoinositide turnover in human neuroblastoma SH-SY5Y and rat cerebellar granule cells.

Authors:  W W Lin; C W Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

Review 3.  Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms.

Authors:  E A Barnard; J Simon; T E Webb
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

4.  Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells.

Authors:  P Sabala; R Czajkowski; K Przybyłek; K Kalita; L Kaczmarek; J Barańska
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Pyrimidinoceptor-mediated activation of phospholipase C and phospholipase A2 in RAW 264.7 macrophages.

Authors:  W W Lin; Y T Lee
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 6.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

7.  Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists.

Authors:  B Grobben; P Claes; D Roymans; E L Esmans; H Van Onckelen; H Slegers
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

8.  P2-purigenic receptors regulate phospholipase C and adenylate cyclase activities in immortalized Schwann cells.

Authors:  L N Berti-Mattera; P L Wilkins; Z Madhun; D Suchovsky
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

9.  Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages.

Authors:  B C Chen; C M Lee; W W Lin
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

10.  Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells.

Authors:  Rafal Czajkowski; Wiktor Banachewicz; Olga Ilnytska; Ludmila B Drobot; Jolanta Baranska
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.